Accepted for Publication: August 13, 2013.
Published Online: March 12, 2014. doi:10.1001/jamadermatol.2013.7444.
Study concept and design: Ally, Tang, Joseph, Mackay-Wiggan, Epstein.
Acquisition of data: All authors.
Analysis and interpretation of data: Ally, Tang, Joseph, Thompson, Chanana, Epstein.
Drafting of the manuscript: Ally, Tang, Lindgren, Raphael, Ulerio.
Critical revision of the manuscript for important intellectual content: Ally, Tang, Joseph, Thompson, Chanana, Mackay-Wiggan, Bickers, Epstein.
Statistical analysis: Ally, Tang, Epstein.
Obtained funding: Tang, Bickers, Epstein.
Administrative, technical, or material support: Ally, Tang, Joseph, Thompson, Lindgren, Raphael, Ulerio, Mackay-Wiggan.
Study supervision: Tang, Mackay-Wiggan, Epstein.
Conflict of Interest Disclosures: Drs Tang and Epstein reported being consultants for Genentech. Dr Epstein also reported being a consultant for Novartis and owning stock options in Curis and Infinity. No other disclosures were reported.
Funding/Support: This study was supported by Genentech, a Clinical and Translational Science Award (UL1RR02413) from the National Institutes of Health, grants 1K23AR056736 (Dr Tang) and 5P30AR044535-11 (Dr Bickers) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant R01CA109584 from the National Cancer Institute (Dr Epstein), a Clinical Investigator Award (CI-54-11) from the Damon Runyon Cancer Research Foundation (Dr Tang), and funding from the Swim Across America Foundation and the Michael J. Rainen Family Foundation.
Role of the Sponsor: Genentech supplied the medication and read drafts of the manuscript for clarity.